# COVID-19; SARS-CoV-2 Infection FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/covid-19-sars-cov-2-infection

> 2 upcoming FDA catalysts in COVID-19; SARS-CoV-2 Infection: ibuzatrelvir (PFE) on October 2027 (primary completion); ibuzatrelvir (PFE) on Oct 2027 to Jan 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 12, 2026 | [Nvx-cov2705 primary completion](https://sec-api.dev/pdufa/nvx-cov2705) | SNY | COVID-19; SARS-CoV-2 Infection | completed | "NCT07079670 (Safety and Immunogenicity of NVX-CoV2705): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07079670)) |
| May 1, 2026 | [Bnt162b2 (2025/2026 recommended sars-cov-2 strain) primary completion](https://sec-api.dev/pdufa/bnt162b2-2025-2026-recommended-sars-cov-2-strain) | BNTX | COVID-19; SARS-COV-2 Infection | completed | "NCT07069309 (A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-01 (ACTUAL); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07069309)) |
| July 24, 2026 | [Bnt162b2 (2025/2026 formulation) primary completion](https://sec-api.dev/pdufa/bnt162b2-2025-2026-formulation) | BNTX | COVID-19; SARS-COV-2 Infection | completed | "NCT07222384 (A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-24 (ACTUAL); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222384)) |
| September 22, 2026 | [Bnt162b2 vaccine primary completion](https://sec-api.dev/pdufa/bnt162b2-vaccine) | BNTX | COVID-19; SARS-COV-2 Infection | completed | "NCT07300839 (A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07300839)) |
| Sep to Dec 2026 | [Bnt162b2 vaccine topline data readout](https://sec-api.dev/pdufa/bnt162b2-vaccine) | BNTX | COVID-19; SARS-COV-2 Infection | scheduled | "NCT07300839 (A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07300839)) |
| October 2027 | [Ibuzatrelvir primary completion](https://sec-api.dev/pdufa/ibuzatrelvir) | PFE | COVID-19 SARS-CoV-2 Infection | scheduled | "NCT06679140 (A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-01 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06679140)) |
| Oct 2027 to Jan 2028 | [Ibuzatrelvir topline data readout](https://sec-api.dev/pdufa/ibuzatrelvir) | PFE | COVID-19 SARS-CoV-2 Infection | scheduled | "NCT06679140 (A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-01 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06679140)) |

## Drugs

- [Nvx-cov2705](https://sec-api.dev/pdufa/nvx-cov2705) (SNY)
- [Bnt162b2 (2025/2026 recommended sars-cov-2 strain)](https://sec-api.dev/pdufa/bnt162b2-2025-2026-recommended-sars-cov-2-strain) (BNTX)
- [Bnt162b2 (2025/2026 formulation)](https://sec-api.dev/pdufa/bnt162b2-2025-2026-formulation) (BNTX)
- [Bnt162b2 vaccine](https://sec-api.dev/pdufa/bnt162b2-vaccine) (BNTX)
- [Ibuzatrelvir](https://sec-api.dev/pdufa/ibuzatrelvir) (PFE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/covid-19-sars-cov-2-infection.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "COVID-19; SARS-CoV-2 Infection FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/covid-19-sars-cov-2-infection

```bibtex
@misc{secapidev_indications_covid_19_sars_cov_2_infection_20261116,
  title        = {COVID-19; SARS-CoV-2 Infection FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/covid-19-sars-cov-2-infection}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_covid_19_sars_cov_2_infection_20261116","title":"COVID-19; SARS-CoV-2 Infection FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/covid-19-sars-cov-2-infection","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
